Topic is now suspended
Status Suspended
Process STA 2018
ID number 2714

Provisional Schedule

Expected publication 19 May 2021


Key events during the development of the guidance:

Date Update
14 February 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714] The company have advised that they will not be seeking regulatory approval for nivolumab for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred, NICE will continue to monitor the situation and update interested parties if or when the situation changes.
10 January 2020 In progress. Referred October 28 2019
14 February 0202 Suspended. Topic is now suspended

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance